HomeCompareHARP vs GBDC

HARP vs GBDC: Dividend Comparison 2026

HARP yields 8.69% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBDC wins by $20.81M in total portfolio value
10 years
HARP
HARP
● Live price
8.69%
Share price
$23.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$35.6K
Annual income
$1,504.59
Full HARP calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — HARP vs GBDC

📍 GBDC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHARPGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HARP + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HARP pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HARP
Annual income on $10K today (after 15% tax)
$738.81/yr
After 10yr DRIP, annual income (after tax)
$1,278.90/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, GBDC beats the other by $13,981,844.85/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HARP + GBDC for your $10,000?

HARP: 50%GBDC: 50%
100% GBDC50/50100% HARP
Portfolio after 10yr
$10.44M
Annual income
$8,226,119.21/yr
Blended yield
78.77%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on HARP right now

HARP
Analyst Ratings
7
Buy
2
Hold
Consensus: Buy
Price Target
$700.00
+2942.2% upside vs current
Range: $700.00 — $700.00
Altman Z
0.4
Piotroski
2/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HARP buys
0
GBDC buys
0
No recent congressional trades found for HARP or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHARPGBDC
Forward yield8.69%11.86%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$35.6K$20.85M
Annual income after 10y$1,504.59$16,450,733.83
Total dividends collected$11.9K$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy
Analyst price target$700.00$14.00

Year-by-year: HARP vs GBDC ($10,000, DRIP)

YearHARP PortfolioHARP Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$11,569$869.19$12,492$1,791.70$923.00GBDC
2$13,319$939.79$16,527$3,160.58$3.2KGBDC
3$15,262$1,011.14$23,588$5,904.90$8.3KGBDC
4$17,414$1,082.88$37,141$11,901.65$19.7KGBDC
5$19,787$1,154.69$66,205$26,463.38$46.4KGBDC
6$22,399$1,226.25$137,452$66,612.65$115.1KGBDC
7$25,264$1,297.27$342,372$195,298.53$317.1KGBDC
8$28,400$1,367.49$1,053,292$686,954.33$1.02MGBDC
9$31,824$1,436.67$4,111,439$2,984,416.95$4.08MGBDC
10$35,557$1,504.59$20,849,974$16,450,733.83$20.81MGBDC

HARP vs GBDC: Complete Analysis 2026

HARPStock

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian and pancreatic cancer, and other mesothelin-expressing tumors. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Full HARP Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this HARP vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HARP vs SCHDHARP vs JEPIHARP vs OHARP vs KOHARP vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.